Your browser doesn't support javascript.
loading
Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort study.
Zhang, Yi; Shen, Guoyi; Xu, Rongyu; Huang, Guozhong; Huang, Zhijun; Duan, Hongbing; Yang, Shengsheng; Zheng, Qingfeng; Yang, Libao; Liu, Rongxing; Ma, Liangyun; Chen, Shaogeng; Yi, Yunfeng; Zhang, Zheming; Li, Kezhi; Birdas, Thomas J; Koyanagi, Kazuo; Simone, Charles B.
Afiliación
  • Zhang Y; Department of Cardiothoracic Surgery, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, China.
  • Shen G; Department of Cardiothoracic Surgery, Zhangzhou Hospital Affiliated to Fujian Medical University, Zhangzhou, China.
  • Xu R; Department of Thoracic Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
  • Huang G; Department of Thoracic Surgery, Affiliated Hospital of Putian University, Putian, China.
  • Huang Z; Department of Gastrointestinal and Esophageal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
  • Duan H; Department of Thoracic Surgery, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China.
  • Yang S; Depatment of Cardiothoracic Surgery, The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, China.
  • Zheng Q; Department of Thoracic Surgery, Fujian Cancer Hospital, Fuzhou, China.
  • Yang L; Department of Thoracic Surgery, Sanming Second Hospital, Sanming, China.
  • Liu R; Depatment of Cardiothoracic Surgery, Longyan Second Hospital, Longyan, China.
  • Ma L; Department of Thoracic Surgery, The 910th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Quanzhou, China.
  • Chen S; Department of Thoracic Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
  • Yi Y; Depatment of Cardiothoracic Surgery, Southeast Hospital affiliated to Xiamen University, Xiamen, China.
  • Zhang Z; Department of Thoracic Surgery, The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army Putian Medical District, Putian, China.
  • Li K; Department of Thoracic Surgery, Nanping First Hospital, Nanping, China.
  • Birdas TJ; Division of Cardiothoracic Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Koyanagi K; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa, Japan.
  • Simone CB; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center and New York Proton Center, New York, NY, USA.
J Thorac Dis ; 15(11): 6228-6237, 2023 Nov 30.
Article en En | MEDLINE | ID: mdl-38090323
Background: Camrelizumab has been demonstrated to be a feasible treatment option for locally advanced esophageal squamous cell carcinoma (ESCC) when combined with neoadjuvant chemotherapy. This trial was conducted to investigate the effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with ESCC in daily practice. Methods: This prospective multicenter observational cohort study was conducted at 13 tertiary hospitals in Southeast China. Patients with histologically or cytologically confirmed ESCC [clinical tumor-node-metastasis (cTNM) stage I-IVA] who had received at least one dose of camrelizumab-containing neoadjuvant therapy were eligible for inclusion. Results: Between June 1, 2020 and July 13, 2022, 255 patients were enrolled and included. The median age was 64 (range, 27 to 82) years. Most participants were male (82.0%) and had clinical stage III-IVA diseases (82.4%). A total of 169 (66.3%) participants underwent surgical resection; 146 (86.4%) achieved R0 resection, and 36 (21.3%) achieved pathological complete response (pCR). Grades 3-5 adverse events (AEs) were experienced by 14.5% of participants. Reactive cutaneous capillary endothelial proliferation occurred in 100 (39.2%) of participants and all were grade 1 or 2. Conclusions: Camrelizumab-containing neoadjuvant therapy has acceptable effectiveness and safety profiles in real-life ESCC patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Thorac Dis Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Thorac Dis Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China